2009-11-05 09:04:29 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Sartorius Stedim Biotech S.A. and produced a report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal – 05/11/2009 – SADIF Investment Analytics, announces a new summary due diligence report covering Sartorius Stedim Biotech S.A. (DIM). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Sartorius Stedim Biotech S.A. investor.

Report Summary: Sartorius Stedim Biotech S.A. is an average quality company with a negative outlook. Sartorius Stedim

Biotech S.A. has strong business growth and is run by efficient management. When compared to its closest peer, Audika, Sartorius Stedim Biotech S.A. shows similar overvaluation and is equally likely to underperform the market.

The 8-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Sartorius Stedim Biotech S.A. for long-term investors.

The report has been distributed to Reuters, and forwarded to Yahoo Finance and FT.com. It is available under 'Analyst Reports' from these websites, from multiple professional platforms including Reuters Knowledge, TheMarkets.com, Thomson Research and Capital IQ or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company.php?tickerr=DIM&cod_co ..

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.